Perceptive eClinical and Kayentis have announced a strategic alliance to provide a fully integrated electronic Clinical Outcome Assessment (eCOA) and Interactive Response Technology (IRT) solution for global clinical trials. The collaboration is intended to offer sponsors and contract research organizations an alternative to single-vendor platforms by combining two specialized systems into one coordinated environment.
According to the companies, the partnership is designed to address operational challenges arising from the use of multiple, disconnected digital systems at investigative sites. By reducing system fragmentation and minimizing the number of tools, platforms and data sources in a study, the integrated eCOA–IRT solution is expected to streamline trial execution, enhance data quality and reduce workload at study sites, with the aim of lowering overall study costs.
The combined platform is described as providing several core functions: a unified user experience across both systems, automatic transfer of patient information such as patient numbers and demographics to reduce duplicate data entry, and automated triggering of eCOA and IRT workflows based on incoming data. These features are intended to simplify day-to-day trial operations and support faster decision-making across the study lifecycle, regardless of trial design, phase or disease area.
The companies cited the current clinical trial environment, in which sites may be required to use numerous digital systems within a single study, including IRT, eCOA, electronic data capture, eConsent and study management tools. They noted that this can lead to fragmented workflows, multiple logins, duplicate entries and complex reconciliation processes, particularly as trial protocols grow more complex and data-rich.
Beyond technical integration, Perceptive eClinical and Kayentis stated that the alliance is structured to support smoother study management processes. The joint offering will be administered through a single contract with aligned milestones, which the companies say is intended to reduce operational friction from study setup through to data lock. They indicated that this initial integration is the first step in a broader plan to expand interoperability across the full clinical trial lifecycle.